ReVision Optics Overview
Latest Deal Type
Out of Business
ReVision Optics General Information
Description
Developer of optical technology intended to help in the treatment of presbyopia. The company's technology is used to do a patented refractive surgery to improve near vision that has been lost by the eye's natural aging process, enabling physicians to treat their patients in an enhanced way and give them better eye sight.
ReVision Optics Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
ReVision Optics Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 10. Out of Business |
30-Jan-2018 |
|
00000 |
|
Completed |
Out of Business |
| 9. Later Stage VC (Series F) |
10-Nov-2016 |
0000 |
00000 |
00000 |
Completed |
Generating Revenue |
| 8. Debt - General |
18-Aug-2016 |
0000 |
00000 |
|
Completed |
Generating Revenue |
| 7. Later Stage VC (Series E) |
29-Jul-2013 |
000.00 |
00000 |
00000 |
Completed |
Generating Revenue |
| 6. Later Stage VC (Series E) |
16-Apr-2013 |
0000 |
000.00 |
00000 |
Completed |
Generating Revenue |
| 5. Later Stage VC (Series E) |
25-May-2010 |
0000 |
000.00 |
000.00 |
Completed |
Generating Revenue |
| 4. Later Stage VC (Series D) |
14-May-2007 |
0000 |
000.00 |
000.00 |
Completed |
Generating Revenue |
| 3. Later Stage VC (Series C) |
19-Oct-2005 |
0000 |
000.00 |
000.00 |
Completed |
Generating Revenue |
| 2. Later Stage VC (Series B) |
25-Sep-2003 |
$2.77M |
$5.19M |
000.00 |
Completed |
Generating Revenue |
| 1. Later Stage VC |
25-Sep-2003 |
$2.42M |
$2.42M |
|
Completed |
Generating Revenue |
ReVision Optics Cap Table
To view ReVision Optics‘s complete cap table, request access >>
| Stock |
# of Shares
Authorized |
Par Value |
Dividend Rate (%) |
Original
Issue Price |
Liquidation |
Liquidation
Pref. Multiple |
Conversion Price |
% Owned |
| Series F |
00,000,000 |
00.000000 |
00 |
00.00 |
00.00 |
00 |
00.00 |
00.000 |
| Series E |
00,000,000 |
00.000000 |
00 |
00.00 |
00.00 |
00 |
00.00 |
00.00 |
| Series D |
0,000,000 |
00.000000 |
00 |
00.00 |
00.00 |
00 |
00.00 |
00.000 |
| Series C |
0,000,000 |
00.000000 |
00 |
00.00 |
00.00 |
00 |
00.00 |
0.000 |
| Series B |
247,326 |
$0.000100 |
8% |
$11.22 |
$11.22 |
1x |
$11.22 |
0.29% |
| Series A |
269,500 |
$0.000100 |
8% |
$9.09 |
$9.09 |
1x |
$9.09 |
0.31% |
ReVision Optics Competitors (2)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| SynergEyes |
Venture Capital-Backed |
Carlsbad, CA |
000 |
000.00 |
000000000 |
000.00 |
| 00000000 |
Private Equity-Backed |
Irvine, CA |
00 |
00000 |
00000000000 |
00000 |
ReVision Optics Executive Team (11)
| Name |
Title |
Board Seat |
Contact Info |
| Louis Bunn |
Chief Financial Officer |
|
|
| Michael Crompton |
Vice President, Regulatory Affairs & Quality Assurance and Chief Compliance Officer |
|
|
| Luis Vargas MD |
Vice President of Medical Affairs and Medical Director |
|
|
| Sarah Cannon |
Director of Global Marketing |
|
|
| Lynne Archer |
Vice President of Clinical Affairs |
|
|
3 Former Executives